On September 15, 2026 Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, reported the submission of a marketing authorization application to the European Medicines Agency (EMA) for lirafugratinib as a second-line treatment for patients with advanced/metastatic cholangiocarcinoma (CCA) harboring FGFR2 fusions or rearrangements.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The application is based on results of the Phase 1/2 ReFocus study, of which the primary endpoint is objective response rate (ORR). In advanced/metastatic FGFR2 fusion+ CCA patients after receiving a prior line of systemic therapy, lirafugratinib achieved an ORR of 46.5% as assessed by independent review committee. The median duration of response, a key secondary endpoint, was 11.8 months. Median progression-free survival was 11.3 months, while median overall survival was 22.8 months.
"Lirafugratinib is a novel drug candidate that has demonstrated meaningful clinical activity and a differentiated safety profile consistent with its high selectivity for FGFR2 and sustained inhibitory mechanism," said Dong-Gun Kim, chief executive officer of Elevar. "We will continue to advance the regulatory processes in the United States and European Union while broadening the therapeutic potential of lirafugratinib across multiple solid tumors through our tumor-agnostic clinical development program."
Lirafugratinib is an irreversible inhibitor that selectively targets FGFR2, differentiating it from existing pan-FGFR inhibitors that broadly inhibit FGFR1, FGFR3, and/or FGFR4 in addition to FGFR2. Consistent with its high selectivity, the rates of hyperphosphatemia and diarrhea – adverse events commonly associated with non-selective FGFR inhibitors – were 20.7% and 21.6%, respectively.
Lirafugratinib received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in 2022 and Breakthrough Therapy Designation in 2023. Elevar submitted a New Drug Application for lirafugratinib to the FDA in January 2026, and the application was granted Priority Review. The FDA is currently reviewing the application, with a Prescription Drug User Fee Act target action date of Sept. 25, 2026.
Elevar is also conducting ReFocus202, a global Phase 2 study evaluating lirafugratinib in patients with various solid tumors harboring FGFR2 fusions or rearrangements. Patient enrollment and dosing are currently underway at clinical sites globally, including in the EU, U.K., Korea and U.S. Through this program, Elevar seeks to expand the therapeutic potential of lirafugratinib beyond CCA to a broader range of solid tumors with a FGFR2 fusion or rearrangement.
About Lirafugratinib
Lirafugratinib (aka RLY-4008) is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties. Lirafugratinib is currently being evaluated in a clinical trial to enroll additional patients with previously treated, advanced or metastatic solid tumors other than CCA harboring FGFR2 fusion or rearrangement, who have not been treated with prior FGFR inhibitors. Elevar has an exclusive license to lirafugratinib from Relay Therapeutics, Inc. for commercialization worldwide.
(Press release, Elevar Therapeutics, SEP 15, 2026, View Source [SID1234670882])